MCID: CRB037
MIFTS: 54

Cerebral Palsy

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Cerebral Palsy

MalaCards integrated aliases for Cerebral Palsy:

Name: Cerebral Palsy 38 12 50 51 29 52 41 3 14 69
Infantile Cerebral Palsy 12 69
Cerebral Palsy, Mixed 69
Mixed Cerebral Palsy 50

Classifications:



External Ids:

Disease Ontology 12 DOID:1969
ICD10 33 G80 G80.9
ICD9CM 35 343.8
MeSH 42 D002547
NCIt 47 C34460

Summaries for Cerebral Palsy

NINDS : 51 The term cerebral palsy refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement, muscle coordination, and balance.CP affects the part of the brain that controls muscle movements.  The majority of children with cerebral palsy are born with it, although it may not be detected until months or years later. The early signs of cerebral palsy usually appear before a child reaches 3 years of age. The most common are a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a “scissored” gait; and muscle tone that is either too stiff or too floppy. Other neurological symptoms that commonly occur in individuals with CP include seizures, hearing loss and impaired vision, bladder and bowel control issues, and pain and abnormal sensations. A small number of children have CP as the result of brain damage in the first few months or years of life, brain infections such as bacterial meningitis or viral encephalitis, or head injury from a motor vehicle accident, a fall, or child abuse. The disorder isn't progressive, meaning that the brain damage typically doesn't get worse over time. Risk factors associated with CP do not cause the disorder but can increase a child's chance of being born with the disorder.CP is not hereditary.

MalaCards based summary : Cerebral Palsy, also known as infantile cerebral palsy, is related to cerebral palsy, ataxic, autosomal recessive and spastic diplegia cerebral palsy, and has symptoms including athetosis, back pain and dystonia. An important gene associated with Cerebral Palsy is ADD3 (Adducin 3). The drugs Dexmedetomidine and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include Blood and Umbilical Cord.

Disease Ontology : 12 A brain disease that is caused by damage to the motor control centers of the developing brain during pregnancy, during childbirth or after birth, which affects muscle movement and balance.

NIH Rare Diseases : 50 cerebral palsy refers to a group of neurological disorders that can affect the brain and/or spinal cord. signs and symptoms generally appear during infancy or early childhood and vary based on the type of cerebral palsy (spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy), the severity of the condition and which area(s) of the brain are affected. common features include a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a "scissored" gait; and muscle tone that is either too stiff or too floppy. cerebral palsy is caused by abnormal brain development or damage to the developing brain. most of these problems occur as the baby grows in the womb; however, they can happen at any time during the first 2 years of life. there is no cure for cerebral palsy, but treatment is available to alleviate some symptoms. this may include physical, occupational, and speech therapy; certain medications; surgery; and/or devices (i.e. braces, wheelchairs) to aid in mobility. last updated: 11/18/2015

MedlinePlus : 41 cerebral palsy is a group of disorders that affect a person's ability to move and to maintain balance and posture. the disorders appear in the first few years of life. usually they do not get worse over time. people with cerebral palsy may have difficulty walking. they may also have trouble with tasks such as writing or using scissors. some have other medical conditions, including seizure disorders or mental impairment. cerebral palsy happens when the areas of the brain that control movement and posture do not develop correctly or get damaged. early signs of cerebral palsy usually appear before 3 years of age. babies with cerebral palsy are often slow to roll over, sit, crawl, smile, or walk. some babies are born with cerebral palsy; others get it after they are born. there is no cure for cerebral palsy, but treatment can improve the lives of those who have it. treatment includes medicines, braces, and physical, occupational and speech therapy. nih: national institute of neurological disorders and stroke

Wikipedia : 72 Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood. Signs and... more...

Related Diseases for Cerebral Palsy

Diseases related to Cerebral Palsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 178)
id Related Disease Score Top Affiliating Genes
1 cerebral palsy, ataxic, autosomal recessive 12.4
2 spastic diplegia cerebral palsy 12.4
3 spastic cerebral palsy 12.4
4 dyskinetic cerebral palsy 12.4
5 cerebral palsy, spastic quadriplegic, 1 12.3
6 mixed cerebral palsy 12.2
7 cerebral palsy athetoid 12.2
8 cerebral palsy, spastic quadriplegic, 2 12.2
9 cerebral palsy, spastic quadriplegic, 3 12.1
10 spastic hemiplegia 12.1
11 spastic quadriplegia 12.1
12 spastic diplegia 12.0
13 spastic monoplegia 11.7
14 spasticity 11.4
15 periventricular leukomalacia 11.4
16 hereditary spastic paraplegia 11.3
17 swallowing disorders 11.2
18 athetosis 11.1
19 hypertonia 11.1
20 dysphagia 11.1
21 hypotonia 11.1
22 neonatal stroke 11.1
23 developmental coordination disorder 11.1
24 foot drop 11.1
25 infantile hypotonia 11.1
26 kernicterus 11.1
27 cerebritis 11.1
28 troyer syndrome 11.0
29 intellectual disability - athetosis - microphthalmia 11.0
30 spastic paraplegia 47, autosomal recessive 11.0
31 spastic paraplegia 52, autosomal recessive 11.0
32 parkinsonism-dystonia, infantile 10.9
33 fetal methylmercury syndrome 10.9
34 suprabulbar paresis, congenital 10.9
35 spastic paraplegia 52 10.8
36 spastic paraplegia 50, autosomal recessive 10.8
37 hereditary spastic paraplegia 51 10.8
38 inherited congenital spastic tetraplegia 10.8
39 spastic paraplegia 51, autosomal recessive 10.8
40 congenital laryngeal palsy 10.8
41 mental retardation, autosomal dominant 26 10.8
42 cerebral atrophy 10.8
43 not otherwise specified 3-mga-uria type 10.8
44 floppy infant syndrome 10.8
45 primary aldosteronism, seizures, and neurologic abnormalities 10.8
46 hemiplegia 10.6
47 quadriplegia 10.6
48 paraplegia 10.5
49 hip subluxation 10.2
50 dystonia 10.2

Comorbidity relations with Cerebral Palsy via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Cerebral Palsy:



Diseases related to Cerebral Palsy

Symptoms & Phenotypes for Cerebral Palsy

UMLS symptoms related to Cerebral Palsy:


athetosis, back pain, dystonia, headache, muscle rigidity, pain, sciatica, seizures, syncope, torticollis, tremor, chronic pain, muscle fibrillation, asterixis, abnormality of extrapyramidal motor function, abnormal head movements, vertigo/dizziness, myokymia, sleeplessness

Drugs & Therapeutics for Cerebral Palsy

Drugs for Cerebral Palsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
2
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
3
Dopamine Approved Phase 4,Phase 1 51-61-6, 62-31-7 681
4
Levodopa Approved Phase 4 59-92-7 6047
5
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-84-3 187
6
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1 1134-47-0 2284
7
Magnesium Sulfate Approved, Vet_approved Phase 4,Phase 3,Phase 2 7487-88-9 24083
8
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
9
Pyrimethamine Approved, Vet_approved Phase 4 58-14-0 4993
10
Sulfadiazine Approved, Vet_approved Phase 4 68-35-9 5215
11
Sulfamethoxazole Approved Phase 4 723-46-6 5329
12
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
13
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
14
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 59-30-3 6037
16
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
17
Inulin Approved, Nutraceutical Phase 4 9005-80-5 24763
18 Adrenergic Agents Phase 4,Phase 1
19 Adrenergic Agonists Phase 4,Phase 1
20 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 1
21 Adrenergic alpha-Agonists Phase 4,Phase 1
22 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
23 Analgesics, Non-Narcotic Phase 4,Phase 3
24 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
25 Anesthetics, General Phase 4
26 Anesthetics, Inhalation Phase 4
27 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
28 Hypnotics and Sedatives Phase 4
29 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
30 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
31 Platelet Aggregation Inhibitors Phase 4
32 Autonomic Agents Phase 4,Phase 3,Phase 1
33 Carbidopa, levodopa drug combination Phase 4
34 Dihydroxyphenylalanine Phase 4
35 Dopamine Agents Phase 4,Phase 1
36 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
37 abobotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1
38 Botulinum Toxins Phase 4,Phase 2,Phase 3,Phase 1
39 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 3,Phase 1
40 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1
41 Neuromuscular Agents Phase 4,Phase 2,Phase 3,Phase 1
42 onabotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1
43 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
44 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
45 calcium channel blockers Phase 4,Phase 3,Phase 2
46 Calcium, Dietary Phase 4,Phase 3,Phase 2
47 Tocolytic Agents Phase 4,Phase 3,Phase 2
48 Epoetin alfa Phase 4,Phase 3,Phase 2,Phase 1 113427-24-0
49 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
50 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 612)

id Name Status NCT ID Phase Drugs
1 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
2 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
3 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
4 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
5 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Unknown status NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
6 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
7 Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases Unknown status NCT00796380 Phase 4 Xingnaojing
8 Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children Completed NCT00154830 Phase 4
9 Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy Completed NCT01276015 Phase 4 Botulinum Toxin Type A
10 Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies Completed NCT00964639 Phase 4 Ropivacaine;Saline
11 Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
12 Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
13 Recurrent Crying Spells in Cerebral Palsy Completed NCT01955655 Phase 4 Baclofen
14 Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth Completed NCT00120588 Phase 4 magnesium
15 Post Marketing Surveillance Study of Dysport Completed NCT00210431 Phase 4
16 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4 recombinant human erythropoietin
17 Treatment of Cerebral Toxoplasmosis in HIV/AIDS Completed NCT00367081 Phase 4 TMX-SMX (Bactrim(R));Pyrimethamine plus Sulfadiazine plus leucoverin
18 Effectiveness of Robotic Gait Training and Physical Therapy for Children and Youth With Cerebral Palsy Recruiting NCT02391324 Phase 4
19 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
20 Synbiotic, Prebiotics and Probiotics in Children With Cerebral Palsy and Constipation Recruiting NCT03117322 Phase 4
21 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Recruiting NCT02633241 Phase 4 Dexmedetomidine-Propofol
22 Intrathecal Baclofen (ITB) Delivery Location and Its Effect on Spasticity Recruiting NCT02903823 Phase 4 Baclofen bolus injection
23 Changes of Gas Values in Cord Blood Versus Time and Temperature Not yet recruiting NCT02785367 Phase 4
24 Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy Terminated NCT00549471 Phase 4
25 Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy Withdrawn NCT01386255 Phase 4 Baclofen;placebo
26 Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below 15 Years Unknown status NCT01832454 Phase 2, Phase 3
27 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy Unknown status NCT01489904 Phase 2, Phase 3
28 Targeted Hip Strength Training in Children With Cerebral Palsy (CP) Unknown status NCT01633736 Phase 3
29 Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Patients With Cerebral Paralysis Unknown status NCT01929434 Phase 3
30 Modulation of Brain Plasticity After Perinatal Stroke Unknown status NCT01189058 Phase 2, Phase 3
31 Magnesium Sulfate to Prevent Brain Injury in Premature Infants Unknown status NCT00065949 Phase 3 magnesium sulfate
32 Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy Completed NCT01787344 Phase 3 Botulinum Toxin Type A(Botox®);Botulinum toxin type A(Botulax®)
33 Orthotics in Ambulatory Cerebral Palsy Completed NCT01527162 Phase 3
34 Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy Completed NCT00261131 Phase 3 Botulinum Toxin A
35 The Post-Operative Pain in Cerebral Palsy (POPPIES) Trial Completed NCT01437644 Phase 3 botulinum toxin intramuscular injection
36 Dutch National ITB Study in Children With Cerebral Palsy Completed NCT00367068 Phase 3 baclofen, intrathecal
37 Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy Completed NCT01893411 Phase 3 IncobotulinumtoxinA (16 Units per kg body weight);IncobotulinumtoxinA (12 Units per kg body weight);IncobotulinumtoxinA (4 Units per kg body weight)
38 Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy Completed NCT01905683 Phase 3 IncobotulinumtoxinA (16-20 Units per kg body weight)
39 Static and Dynamic Postural Stability in Cerebral Palsy Children Completed NCT01799304 Phase 3
40 Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Completed NCT00491894 Phase 3 Oral Glycopyrrolate Liquid
41 A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years Completed NCT01898520 Phase 3 Sativex;Placebo
42 Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles Completed NCT00133861 Phase 2, Phase 3 Botulinum toxin
43 Dysport® Pediatric Lower Limb Spasticity Follow-on Study Completed NCT01251380 Phase 3 Botulinum type A toxin (Dysport®)
44 Dysport® Pediatric Lower Limb Spasticity Study Completed NCT01249417 Phase 3 Botulinum type A toxin (Dysport®);Placebo
45 Effects of Mirror Neurons Stimulation on Motor Skill Rehabilitation in Children With Cerebral Palsy Completed NCT01267929 Phase 3
46 Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) Completed NCT00014989 Phase 3 magnesium sulfate
47 Individualized Neurodevelopmental Treatment Completed NCT00922077 Phase 3
48 MEOPA to Improve Physical Therapy Results After Multilevel Surgery Completed NCT00632528 Phase 3 MEOPA;Medicinal air
49 BOTOX® Treatment in Pediatric Lower Limb Spasticity Completed NCT01603628 Phase 3 Normal Saline (Placebo)
50 BOTOX® Treatment in Pediatric Upper Limb Spasticity Completed NCT01603602 Phase 3 Normal Saline (Placebo)

Search NIH Clinical Center for Cerebral Palsy

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cerebral Palsy cell therapies at LifeMap Discovery.

Genetic Tests for Cerebral Palsy

Genetic tests related to Cerebral Palsy:

id Genetic test Affiliating Genes
1 Cerebral Palsy 29

Anatomical Context for Cerebral Palsy

MalaCards organs/tissues related to Cerebral Palsy:

39
Brain, Bone, Testes, Spinal Cord, Heart, Eye, Bone Marrow
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cerebral Palsy:
id Tissue Anatomical CompartmentCell Relevance
1 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Cerebral Palsy

Articles related to Cerebral Palsy:

(show top 50) (show all 1512)
id Title Authors Year
1
Effects of an Off-Axis Pivoting Elliptical Training Program on Gait Function in Persons With Spastic Cerebral Palsy: A Preliminary Study. ( 28628539 )
2017
2
Reliability and sources of variation of the ABILHAND-Kids questionnaire in children with cerebral palsy. ( 28068864 )
2017
3
Structured skill practice during intensive bimanual training leads to better trunk and arm control than unstructured practice in children with unilateral spastic cerebral palsy. ( 27912104 )
2017
4
Role of Anesthesiologist in the Management of a Child with Cerebral Palsy. ( 28928544 )
2017
5
Biofeedback interventions for people with cerebral palsy: a systematic review protocol. ( 28086958 )
2017
6
Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules. ( 28385185 )
2017
7
What areas of functioning are influenced by aquatic physiotherapy? Experiences of parents of children with cerebral palsy. ( 28933572 )
2017
8
Cortical bone deficit and fat infiltration of bone marrow and skeletal muscle in ambulatory children with mild spastic cerebral palsy. ( 27732905 )
2017
9
Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy. ( 28237420 )
2017
10
Chorioamnionitis in the Development of Cerebral Palsy: A Meta-analysis and Systematic Review. ( 28814548 )
2017
11
Immediate effects of quick trunk movement exercise on sit-to-stand movement in children with spastic cerebral palsy: a pilot study. ( 28603369 )
2017
12
Umbilical cord blood cells for treatment of cerebral palsy; timing and treatment options. ( 28937975 )
2017
13
Reliability and validity of the Korean-language version of the Communication Function Classification System in children with cerebral palsy. ( 28929518 )
2017
14
Health self-management, transition readiness and adaptive behavior in persons with cerebral palsy or myelomeningocele. ( 28836807 )
2017
15
Effect of neurodevelopmental treatment-based physical therapy on the change of muscle strength, spasticity, and gross motor function in children with spastic cerebral palsy. ( 28626301 )
2017
16
Clinical presentation and management of dyskinetic cerebral palsy. ( 28816119 )
2017
17
White matter integrity in dyskinetic cerebral palsy: Relationship with intelligence quotient and executive function. ( 28702354 )
2017
18
Therapy access among children with autism spectrum disorder, cerebral palsy, and attention-deficit-hyperactivity disorder: a population-based study. ( 28940224 )
2017
19
Neurophysiological mechanisms and functional impact of mirror movements in children with unilateral spastic cerebral palsy. ( 28884806 )
2017
20
Comparative study on gastrostomy and orally nutrition of children and adolescents with tetraparesis cerebral palsy. ( 28954047 )
2017
21
Serious incident investigations for cerebral palsy are "poor quality," says watchdog. ( 28935821 )
2017
22
First words: speech and language interventions in cerebral palsy. ( 28090650 )
2017
23
Can parents provide hand function training for their child with cerebral palsy? ( 28083905 )
2017
24
Serial Casting as an Adjunct to Botulinum Toxin Type A Treatment in Children With Cerebral Palsy and Spastic Paraparesis With Scissoring of the Lower Extremities. ( 28393669 )
2017
25
Results and complications of percutaneous pelvic osteotomy and intertrochanteric varus shortening osteotomy in 54 consecutively operated GMFCS level IV and V cerebral palsy patients. ( 28083677 )
2017
26
Comparing behavioral treatment of feeding difficulties and tube dependence in children with cerebral palsy and autism spectrum disorder. ( 28946574 )
2017
27
Transient Changes in Brain Metabolites after Transcranial Direct Current Stimulation in Spastic Cerebral Palsy: A Pilot Study. ( 28824525 )
2017
28
Central Precocious Puberty and Response to GnRHa Therapy in Children with Cerebral Palsy and Moderate to Severe Motor Impairment: Data from a Longitudinal, Case-Control, Multicentre, Italian Study. ( 28791047 )
2017
29
Three-dimensional lumbar segment movement characteristics during paediatric cerebral palsy gait. ( 28088678 )
2017
30
Hyperbaric oxygen therapy is safe and effective for the treatment of sleep disorders in children with cerebral palsy. ( 28079475 )
2017
31
Bilateral globus pallidus internus deep brain stimulation for dyskinetic cerebral palsy supports success of cochlear implantation in a 5-year old ex-24A week preterm twin with absent cerebellar hemispheres. ( 28017556 )
2017
32
Are we there yet? Celebrating progress in cerebral palsy research. ( 28940188 )
2017
33
Evaluation of Functional Mobility Outcomes Following Electrical Stimulation in Children With Spastic Cerebral Palsy. ( 28393668 )
2017
34
Use of virtual reality intervention to improve reaction time in children with cerebral palsy: A randomized controlled trial. ( 28933977 )
2017
35
Should Proximal Femoral Implants be Removed Prophylactically or Reactively in Children With Cerebral Palsy? ( 28945691 )
2017
36
Bony reconstruction of hip in cerebral palsy children Gross Motor Function Classification System levels III to V: a systematic review. ( 28953164 )
2017
37
Effect of cerebrolysin on gross motor function of children with cerebral palsy: a clinical trial. ( 28074392 )
2017
38
Lumbosacral Dorsal Rhizotomy for Spastic Cerebral Palsy: A Health Technology Assessment. ( 28757906 )
2017
39
Medical treatment of dyskinetic cerebral palsy: translation into practice. ( 28892137 )
2017
40
Efficacy of oral pharmacological treatments in dyskinetic cerebral palsy: a systematic review. ( 28872668 )
2017
41
Coaction of individual and environmental factors: a review of intensive therapy paradigms for children with unilateral spastic cerebral palsy. ( 28749087 )
2017
42
Changes in Cardiorespiratory Responses and Kinematics With Hippotherapy in Youth With and Without Cerebral Palsy. ( 28075704 )
2017
43
Inter and Intra Rater Reliability of the 10 Meter Walk Test in the Community Dweller Adults with Spastic Cerebral Palsy. ( 28277557 )
2017
44
Yes We Can! A Phenomenological Study of a Sports Camp for Young People With Cerebral Palsy. ( 28942669 )
2017
45
Bone mineral density and insulin-like growth factor-1 in children with spastic cerebral palsy. ( 28236062 )
2017
46
Influence of trunk control and lower extremity impairments on gait capacity in children with cerebral palsy. ( 28944697 )
2017
47
Dopa-responsive Dystonia in a Child Misdiagnosed as Cerebral Palsy. ( 28904579 )
2017
48
Transdermal Scopolamine Withdrawal Syndrome Case Report in the Pediatric Cerebral Palsy Population. ( 28081025 )
2017
49
Whole-brain structural connectivity in dyskinetic cerebral palsy and its association with motor and cognitive function. ( 28608616 )
2017
50
Functional electrical stimulation of the ankle dorsiflexors during walking in spastic cerebral palsy: a systematic review. ( 28815571 )
2017

Variations for Cerebral Palsy

ClinVar genetic disease variations for Cerebral Palsy:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 ADD3 NM_016824.4(ADD3): c.1100G> A (p.Gly367Asp) single nucleotide variant Pathogenic rs564185858 GRCh37 Chromosome 10, 111882007: 111882007

Expression for Cerebral Palsy

Search GEO for disease gene expression data for Cerebral Palsy.

Pathways for Cerebral Palsy

GO Terms for Cerebral Palsy

Sources for Cerebral Palsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....